Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Josamycin** is a macrolide antibiotic produced by *Streptomyces narbonensis* (var. *josamyceticus*) and used for the treatment of various susceptible bacterial infections, including respiratory tract infections, skin infections, otorhinological (ear/nose/throat) infections, urinary tract infections, biliary tract infection, breast infection, dental and oral soft tissue infections, genital infection, and some sexually transmitted diseases[1][4][6][8]. It acts by binding reversibly to the 50S subunit of the bacterial ribosome and inhibiting protein biosynthesis through blockage of transpeptidation/translocation reactions. This results in inhibition of cell growth; its action is mainly bacteriostatic but can be bactericidal at high concentrations[1][5]. It has a broad spectrum of activity against many Gram-positive bacteria as well as some Gram-negative bacteria and atypical pathogens such as mycoplasmas, spirochetes, chlamydias and rickettsias[5][6]. Unlike erythromycin it does not induce macrolide resistance in staphylococci and appears to have fewer gastrointestinal side effects[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on josamycin.